Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.56 -0.02 (-0.07%)
Streaming Delayed Price Updated: 11:12 AM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Argus Turns Bullish On Pfizer, Highlights GLP-1 And Oncology Pipeline ↗
Via Talk Markets
News headline image
Forget Teva: This Dividend Top Dog Is the Real Value Buy Today ↗
Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead. 
Via The Motley Fool
Topics Intellectual Property
TechMediaBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Appoints Bat-Sheva Noy as Vice President of Global Sales
Via Investor Brand Network
News headline image
The Dividend Safe Harbor: 2 Stocks to Watch ↗
Rising geopolitical tensions, surging oil prices, and increasing volatility are pressuring U.S. equities and driving a shift toward defensive positioning. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Higher Income or Ironclad Safety? VCIT vs. IEI ↗
Explore how portfolio risk, bond type, and diversification set these two fixed income ETFs apart for different investor priorities. 
Via The Motley Fool
Topics Bonds ETFs
News headline image
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent... 
Via Finterra
Topics Economy Initial Public Offering Retirement
News headline image
Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceu... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell ↗
The reason is so compelling that I actually did buy the stock -- and I have no plans to sell. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need ↗
Don't follow general market sentiment when it comes to these two stocks. 
Via The Motley Fool
News headline image
Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead? ↗
Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole ↗
Sorry, Teva, it's not you ... it's me. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety
As the final reports of the fourth-quarter earnings season trickled in through late February 2026, the S&P 500 demonstrated a resilient performance that caught many analysts by surprise. The benchmark... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
The Implementation Pivot: How Accenture Defied the ‘SaaS-pocalypse’ with a Massive AI Rebound
As of February 27, 2026, the global technology sector is grappling with a profound identity crisis often dubbed the "SaaS-pocalypse." While many software-as-a-service providers have seen their... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag
The fourth-quarter 2025 earnings season has delivered a definitive verdict on the health of the American economy: the "Industrial Renaissance" is no longer a forecast, but a realized phenomenon. While... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan
As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional... 
Via MarketMinute
Topics Artificial Intelligence ETFs
News headline image
Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?
Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects. 
Via Barchart.com
Topics Stocks
News headline image
The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines
As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of... 
Via Finterra
Topics Economy
News headline image
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗
Amneal (AMRX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? ↗
Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology. 
Via Stocktwits
Topics Earnings
News headline image
2 Reasons to Like ZTS (and 1 Not So Much)
Over the last six months, Zoetis’s shares have sunk to $129.91, producing a disappointing 16.4% loss - a stark contrast to the S&P 500’s 7.2% gain. This may have investors wondering how to approach the... 
Via StockStory
Topics Stocks
News headline image
OPKO Health (OPK) Q4 2025 Earnings Call Transcript ↗
OPKO Health (OPK) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.
Even amid volatility, Pfizer keeps rewarding shareholders year after year. 
Via Barchart.com
Topics Artificial Intelligence
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy
As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the... 
Via Finterra
Topics Economy
News headline image
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 5% year on year to $3.7 billion. The company’s full-year revenue guidance of... 
Via StockStory
News headline image
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash ↗
Koyfin analysts expect revenue to grow nearly 28% from the last quarter and forecast losses to narrow significantly. 
Via Stocktwits
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,... 
Via MarketMinute
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.